Compare
Drugs Made In America Acquisition II Corp. vs EQV Ventures Acquisition Corp. II vs Cantor Equity Partners IV, Inc. vs Innventure, Inc.
| Latest fiscal year | Drugs Made In America Acquisition II Corp. DMII | EQV Ventures Acquisition Corp. II EVAC | Cantor Equity Partners IV, Inc. CEPF | Innventure, Inc. INV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $2.06M |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | -815.9% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | $4.19M | $8.92M | $6.13M | -$293.32M |
| EPS (Diluted) | n/a | n/a | n/a | -$5.39 |
| Operating cash flow | -$1.02M | -$627.9K | -$62.9K | -$80.68M |
| Free cash flow | n/a | n/a | n/a | -$82.10M |
| Cash & equivalents | $223 | $1.09M | $25.0K | $60.45M |
| Total assets | $504.96M | $470.27M | $456.95M | $599.19M |
| Total liabilities | $17.80M | $18.13M | $95.4K | $115.51M |
| Shareholders' equity | -$17.77M | -$16.38M | $142.4K | $204.21M |
| Return on year-end equity | n/a | n/a | n/m | -143.6% |
| Shares outstanding | 13.70M | n/a | n/a | 67.74M |
Revenue, most recent five fiscal years
| Fiscal year | Drugs Made In America Acquisition II Corp. | EQV Ventures Acquisition Corp. II | Cantor Equity Partners IV, Inc. | Innventure, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $2.06M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | n/a |
| 2 years earlier | n/a | n/a | n/a | $1.12M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |